Disclosure Plus

Genexine, Inc. to Rely on NeoImmuneTech, Inc. for 85% of This Year’s Revenue… Uncertainty Rises for Next Year

KIM SAE-MI
2026-11-19 12:01:01
[Edaily Reporter KIM SAE-MI ] It has been revealed that Genexine, Inc.(095700)generated 85% of its revenue this year from its U.S. affiliate, NeoImmuneTech, Inc.(950220). In particular, as the company has received all milestone payments related to the technology transfer and development of a new drug—which accounted for the majority of its revenue—attention is now focused on the sustainability of its revenue next year. The company expects to receive a share of the revenue generated from NeoImmuneTech, Inc.’s subsequent technology transfer agreements.

Genexine, Inc. headquarters (Photo: ReporterKIM SAE-MI )

Genexine, Inc. Accounted for 85% of Revenue… $12.5 Million in Technology Fees Paid in Full
According to the Financial Supervisory Service’s electronic disclosure system on the 18th,
Genexine, Inc.’s
cumulative
revenue
for the first three quarters of this year totaled 5.5 billion won. Of this, revenue related to NeoImmuneTech, Inc. amounted to 4.7 billion won, accounting for 84.7% of the total.

NeoImmuneTech, Inc. is not only an affiliate in which Genexine, Inc. holds a 16.29% stake but also a U.S. biotech company currently conducting research and development (R&D) on the immuno-oncology candidate “GX-I7,” which it licensed from Genexine, Inc. Although NeoImmuneTech, Inc. has pursued more than 20 clinical trials using GX-I7, it has suspended or terminated a significant number of its development programs. As of the end of the third quarter, there were five ongoing GX-I7 clinical trials, all of which are investigator-initiated trials (IITs). NeoImmuneTech, Inc. is currently focusing on two CAR-T combination trials targeting large B-cell lymphoma and multiple myeloma, as well as the development of a treatment for acute radiation syndrome.

Previously, Genexine, Inc. transferred the rights to GX-I7 for the Americas and Europe to NeoImmuneTech, Inc. in 2015. The agreement was valued at a total of $12.5 million (13.9 billion won), including an upfront payment of $4.5 million (approximately 5 billion won at the time of the agreement) and development milestones totaling $8 million (8.9 billion won).

Of Genexine, Inc.’s revenue related to NeoImmuneTech, Inc. this year, 4.2 billion won comes from development milestones under the GX-I7 technology transfer agreement. Genexine, Inc. received the final development milestone payment of $3 million (approximately 4.2 billion won) from NeoImmuneTech, Inc. last August. With the receipt of this final milestone payment this year, all upfront payments and development milestone payments specified in the original agreement have been paid in full.

A Genexine, Inc. official stated, “This year’s milestone was related to clinical trials,” adding, “There are no further milestones to be received (from NeoImmuneTech, Inc.).”

With the technology transfer agreement concluded 11 years ago, Genexine, Inc. now faces the challenge of securing new revenue streams. Since the one-time technology fee revenue—which accounted for a significant portion of this year’s revenue—has ended, the company will likely need to fill the gap with additional technology transfer revenue or sales from research services.

“Now Anticipating Revenue Sharing from the Tolerance Bio Agreement”
Of the 4.7 billion won in revenue related to NeoImmuneTech, Inc., 500 million won—excluding existing development milestones—came from revenue sharing resulting from the grant of a sublicense for GX-I7. The GX-I7 technology transfer agreement signed between Genexine, Inc. and NeoImmuneTech, Inc. includes a clause stipulating that 35% of revenue from third-party technology transfers must be allocated to Genexine, Inc.

Last August, NeoImmuneTech, Inc. transferred the rights to develop and commercialize “NT-I7” (GX-I7) for the indication of thymic insufficiency to Tolerance Bio, Inc. in the U.S. Under the terms of the agreement, NeoImmuneTech received a 4% equity stake in Tolerance Bio, Inc. in lieu of a cash upfront payment and is set to receive milestone payments totaling up to $260 million (approximately 360.7 billion won) upon achieving future development and sales targets.

NeoImmuneTech, Inc. valued the Tolerance Bio equity received in lieu of an upfront payment at 1.6 billion won and recognized it as revenue in the third quarter of this year. In other words, it recognized shares in an unlisted company—rather than cash—as revenue. It is understood that 35% of this amount—500 million won—was also reflected in Genexine, Inc.’s revenue. A Genexine, Inc. official explained, “(The 500 million won) is revenue generated when NeoImmuneTech, Inc. transferred the technology to Tolerance Bio.”

Furthermore, Genexine, Inc. anticipates additional revenue from NeoImmuneTech, Inc.’s subsequent technology transfer agreements. A Genexine, Inc. spokesperson noted, “Next year, we are also set to receive 35% of the upfront payment from the contract between Tolerance Bio and NeoImmuneTech, Inc.”

Earned 4.7 billion won in Royalties Through NeoImmuneTech, Inc.
, but
Equity Value Declined by 3.3 Billion Won
Although Genexine, Inc. secured royalty revenue
through
NeoImmuneTech, Inc. this year, the book value of its equity stake decreased. This was due to an equity method loss resulting from NeoImmuneTech, Inc.’s ongoing losses.

The book value of Genexine, Inc.’s 16.29% stake in NeoImmuneTech, Inc. decreased by 3.3 billion won, from 17.2 billion won at the end of last year to 13.9 billion won at the end of September this year. The cumulative equity method loss related to NeoImmuneTech, Inc. for the first three quarters of this year totaled 2.4 billion won. In essence, NeoImmuneTech, Inc.’s business performance is affecting not only Genexine, Inc.’s revenue but also the value of its investment assets.

Genexine, Inc. has recently been pushing to sell investment assets to improve its financial structure. In fact, the board of directors has approved proposals to dispose of investment assets three times this year alone—in May, July, and August.

When Edaily asked about the possibility of selling stakes in affiliates such as NeoImmuneTech, Inc., the company responded, “It is difficult to casually sell our stakes in ToolGen Incorporated(199800)and NeoImmuneTech, Inc., in which Genexine, Inc. is the largest shareholder,” adding, “We expect to continue holding them for the time being.”

Economy

Corporation

IT·Science

Economy

Flybit Strengthens Anti-Money Laundering Measures and User Protection

Korea Digital Exchange, which operates the digital asset (virtual asset) exchange Flybit, has taken steps to strengthen anti-money laundering measures and user protection. Korea Digital Asset Exchange…
2026-11-19 12:45:27

Corporation

After Enhancing the Flavor and Adding Protein… TakeFit Sees Sales Jump 48%

NamyangDairyProducts(003920)’s protein brand “TakeFit” saw its cumulative sales for the third quarter of this year increase by 48.3% compared to the same period last year. Analysts attribute this grow…
2026-11-19 09:14:40

IT·Science

Shinwon, CEO of kakaopay, Participates in the “Finance That Saves Lives” Campaign

kakaopay(377300)has participated in the “Finance That Saves Lives” campaign organized by the Korea Inclusive Finance Agency. The “Finance That Saves Lives Campaign” is a public service campaign organi…
2026-11-19 12:58:00